WALTHAM - Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from multiple trials across its.
Fecal microbiota profiles differ among patients with melanoma and those without as well as between patients with early stage and late-stage disease, new data suggest.